These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 7151322)

  • 1. Hemodialysis in the treatment of life-threatening hyperphosphatemia.
    Feig PU; Hirszel P; Galen MA; Rosenworcel E; Raisz LG
    Clin Exp Dial Apheresis; 1982; 6(2-3):105-11. PubMed ID: 7151322
    [No Abstract]   [Full Text] [Related]  

  • 2. New developments in hyperphosphatemia management.
    Slatopolsky E
    J Am Soc Nephrol; 2003 Sep; 14(9 Suppl 4):S297-9. PubMed ID: 12939384
    [No Abstract]   [Full Text] [Related]  

  • 3. Effect of short-term low-protein diet supplemented with keto acids on hyperphosphatemia in maintenance hemodialysis patients.
    Li H; Long Q; Shao C; Fan H; Yuan L; Huang B; Gu Y; Lin S; Hao C; Chen J
    Blood Purif; 2011; 31(1-3):33-40. PubMed ID: 21135547
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Initiation of Sevelamer and Mortality among Hemodialysis Patients Treated with Calcium-Based Phosphate Binders.
    Komaba H; Wang M; Taniguchi M; Yamamoto S; Nomura T; Schaubel DE; Smith AR; Zee J; Karaboyas A; Bieber B; Fukagawa M; Tentori F
    Clin J Am Soc Nephrol; 2017 Sep; 12(9):1489-1497. PubMed ID: 28724618
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intensified treatment of hyperphosphatemia associated with reduction in parathyroid hormone in patients on maintenance hemodialysis.
    Chen L; He JX; Chen YY; Ling YS; Lin CH; Guan TJ
    Ren Fail; 2018 Nov; 40(1):15-21. PubMed ID: 29295646
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of hyperphosphatemia with sevelamer hydrochloride in hemodialysis patients: a comparison with calcium acetate.
    Hervás JG; Prados D; Cerezo S
    Kidney Int Suppl; 2003 Jun; (85):S69-72. PubMed ID: 12753270
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Importance of the "adequate blood phosphorus" concept as a risk factor for hyperphosphatemia].
    Douthat WG; Alles A; Marinovich S; Tirado S; Peñalba A; Prudkin S
    Nefrologia; 2003; 23 Suppl 2():95-9. PubMed ID: 12778863
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of hyperphosphatemia with calcium citrate in hemodialysis patients.
    Saupe J; Belmega G; Krause R; Bennhold I
    Nephron; 1989; 52(1):93-4. PubMed ID: 2710274
    [No Abstract]   [Full Text] [Related]  

  • 9. Sevelamer hydrochloride improves hyperphosphatemia in hemodialysis patients with low bone turnover rate and low intact parathyroid hormone levels.
    Kokuho T; Toya Y; Kawaguchi Y; Tamura K; Iwatsubo K; Dobashi Y; Nakazawa A; Takeda H; Iwatsubo M; Hirawa N; Yasuda G; Ohnishi T; Umemura S
    Ther Apher Dial; 2007 Dec; 11(6):442-8. PubMed ID: 18028171
    [TBL] [Abstract][Full Text] [Related]  

  • 10. One year efficacy and safety of lanthanum carbonate for hyperphosphatemia in Japanese chronic kidney disease patients undergoing hemodialysis.
    Shigematsu T;
    Ther Apher Dial; 2010 Feb; 14(1):12-9. PubMed ID: 20438515
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Calcium, phosphate, and PTH levels in the hemodialysis population: a multicenter study.
    Gallieni M; Cucciniello E; D'Amaro E; Fatuzzo P; Gaggiotti A; Maringhini S; Rotolo U; Brancaccio D;
    J Nephrol; 2002; 15(2):165-70. PubMed ID: 12018633
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Two phosphAte taRGets in End-stage renal disease Trial (TARGET): A Randomized Controlled Trial.
    Wald R; Rabbat CG; Girard L; Garg AX; Tennankore K; Tyrwhitt J; Smyth A; Rathe-Skafel A; Gao P; Mazzetti A; Bosch J; Yan AT; Parfrey P; Manns BJ; Walsh M
    Clin J Am Soc Nephrol; 2017 Jun; 12(6):965-973. PubMed ID: 28550080
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Calcium carbonate for the treatment of hyperphosphatemia in chronic hemodialysis patients].
    Kiss D; Battegay M; Meier C; Lyrer A
    Schweiz Med Wochenschr; 1990 Mar; 120(9):295-8. PubMed ID: 2315655
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of daily dialysis in the control of hyperphosphatemia.
    Achinger SG; Ayus JC
    Kidney Int Suppl; 2005 Jun; (95):S28-32. PubMed ID: 15882310
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Methods of correcting hyperphosphatemia in chronic renal failure and in dialysis (review)].
    Novikov AI
    Ter Arkh; 1997; 69(12):63-7. PubMed ID: 9503540
    [No Abstract]   [Full Text] [Related]  

  • 16. Extreme hyperphosphatemia and acute renal failure after a phosphorus-containing bowel regimen.
    Orias M; Mahnensmith RL; Perazella MA
    Am J Nephrol; 1999; 19(1):60-3. PubMed ID: 10085452
    [TBL] [Abstract][Full Text] [Related]  

  • 17. When is Vitamin D contraindicated in dialysis patients?
    Lewin E; Olgaard K
    Semin Dial; 2009; 22(3):240-2. PubMed ID: 19572998
    [No Abstract]   [Full Text] [Related]  

  • 18. [Heparin induced mobilization of calcium and inorganic phosphate in connection with extraosseous calcification in chronic hemodialysis].
    Korz R
    Klin Wochenschr; 1971 Jun; 49(12):684-92. PubMed ID: 4996692
    [No Abstract]   [Full Text] [Related]  

  • 19. [Aluminum hydroxide treatment of hyperphosphatemia in uremia].
    Bergquist-Poppen M; Bergström J; Wallin R
    Lakartidningen; 1972 May; 69(19):2319-20. PubMed ID: 5035811
    [No Abstract]   [Full Text] [Related]  

  • 20. When is Vitamin D contraindicated in dialysis patients?
    Brown HJ; Cunningham J
    Semin Dial; 2009; 22(3):237-40. PubMed ID: 19572997
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.